Compare
TriSalus Life Sciences, Inc. vs SANUWAVE Health, Inc. vs Shoulder Innovations, Inc. vs SS Innovations International, Inc.
| Latest fiscal year | TriSalus Life Sciences, Inc. TLSI | SANUWAVE Health, Inc. SNWV | Shoulder Innovations, Inc. SI | SS Innovations International, Inc. SSII |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $45.15M | $44.05M | $47.32M | $42.48M |
| Revenue growth (YoY) | +53.4% | +35.0% | +49.6% | +105.7% |
| Gross margin | 84.6% | 77.1% (computed) | 76.5% | 46.0% |
| Operating margin | -59.7% | 11.2% | -55.6% | -19.3% |
| Net margin | -86.9% | 26.8% | -85.3% | -28.5% |
| Net income | -$39.23M | $11.81M | -$40.36M | -$12.13M |
| EPS (Diluted) | -$1.84 | $0.41 | -$4.65 | -$0.06 |
| Operating cash flow | -$18.01M | $3.88M | -$28.61M | -$18.54M |
| Free cash flow | -$18.93M | $1.93M | -$36.02M | -$22.20M |
| Cash & equivalents | $20.44M | $11.96M | $26.87M | $3.21M |
| Total assets | $35.33M | $37.34M | $169.91M | $74.23M |
| Total liabilities | $69.19M | $35.72M | $29.16M | $36.01M |
| Shareholders' equity | -$33.86M | $1.62M | $140.75M | $38.22M |
| Return on year-end equity | n/a | 729.6% | -28.7% | -31.7% |
| Shares outstanding | 50.00M | 8.59M | 20.62M | 194.17M |
Revenue, most recent five fiscal years
| Fiscal year | TriSalus Life Sciences, Inc. | SANUWAVE Health, Inc. | Shoulder Innovations, Inc. | SS Innovations International, Inc. |
|---|---|---|---|---|
| Latest | $45.15M Ended 2025-12-31 | $44.05M Ended 2025-12-31 | $47.32M Ended 2025-12-31 | $42.48M Ended 2025-12-31 |
| 1 year earlier | $29.43M Ended 2024-12-31 | $32.63M Ended 2024-12-31 | $31.62M Ended 2024-12-31 | $20.65M Ended 2024-12-31 |
| 2 years earlier | $18.51M Ended 2023-12-31 | $20.40M Ended 2023-12-31 | n/a | $5.88M Ended 2023-12-31 |
| 3 years earlier | $12.40M Ended 2022-12-31 | $16.74M Ended 2022-12-31 | n/a | $1.44M Ended 2022-12-31 |
| 4 years earlier | n/a | $13.01M Ended 2021-12-31 | n/a | n/a |